Eyepoint Pharmaceuticals (NASDAQ:EYPT) Cut to “Neutral” at Cantor Fitzgerald

Cantor Fitzgerald cut shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) from an overweight rating to a neutral rating in a report published on Monday, MarketBeat reports.

A number of other equities research analysts have also recently issued reports on the stock. Stifel Nicolaus started coverage on shares of Eyepoint Pharmaceuticals in a research report on Thursday, July 16th. They set a “buy” rating and a $40.00 target price for the company. Chardan Capital restated a “neutral” rating and issued a $5.00 price target (down from $65.00) on shares of Eyepoint Pharmaceuticals in a research report on Monday. HC Wainwright decreased their price objective on shares of Eyepoint Pharmaceuticals from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Royal Bank Of Canada dropped their price objective on shares of Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Eyepoint Pharmaceuticals has a consensus rating of “Hold” and an average target price of $28.11.

Eyepoint Pharmaceuticals Price Performance

Shares of NASDAQ:EYPT opened at $6.30 on Monday. The business’s fifty day moving average price is $12.85 and its two-hundred day moving average price is $13.49. Eyepoint Pharmaceuticals has a fifty-two week low of $3.95 and a fifty-two week high of $19.11. The stock has a market capitalization of $543.12 million, a price-to-earnings ratio of -1.68 and a beta of 1.76.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. The company had revenue of $0.51 million for the quarter, compared to the consensus estimate of $0.45 million. Research analysts expect that Eyepoint Pharmaceuticals will post -3.6 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Stempoint Capital LP lifted its position in Eyepoint Pharmaceuticals by 129.1% during the 1st quarter. Stempoint Capital LP now owns 810,764 shares of the company’s stock worth $10,451,000 after buying an additional 456,915 shares in the last quarter. Janus Henderson Group PLC grew its holdings in Eyepoint Pharmaceuticals by 22.6% during the 1st quarter. Janus Henderson Group PLC now owns 3,601,168 shares of the company’s stock worth $46,419,000 after acquiring an additional 663,439 shares during the last quarter. California State Teachers Retirement System increased its position in Eyepoint Pharmaceuticals by 2,158.3% in the 1st quarter. California State Teachers Retirement System now owns 105,101 shares of the company’s stock valued at $1,355,000 after acquiring an additional 100,447 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in Eyepoint Pharmaceuticals by 58.4% in the 1st quarter. The Manufacturers Life Insurance Company now owns 36,072 shares of the company’s stock valued at $465,000 after acquiring an additional 13,297 shares in the last quarter. Finally, Commodore Capital LP bought a new position in shares of Eyepoint Pharmaceuticals in the first quarter worth about $36,414,000. 99.41% of the stock is owned by institutional investors.

Eyepoint Pharmaceuticals News Roundup

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: EyePoint said the primary-endpoint miss was largely attributable to nine patients—approximately 4% of the study population—who experienced vision loss unrelated to wet AMD. The company also pointed to favorable secondary endpoints, reduced treatment burden and durable disease control, which could preserve the broader DURAVYU investment case. EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs Eylea May Be Overblown
• Positive Sentiment: Upcoming LUCIA Phase 3 data, expected in the fourth quarter of 2026, is now a major catalyst. A positive result could help revive confidence in DURAVYU and partially offset the LUGANO failure.
• Positive Sentiment: Citigroup maintained a buy rating while reducing its price target to $17, implying substantial potential upside if the remaining clinical program succeeds.
• Neutral Sentiment: Unusually active options trading included the purchase of about 3,011 call contracts, above average volume. This may reflect speculative positioning around the stock’s volatility and upcoming clinical catalysts rather than a fundamental improvement.
• Negative Sentiment: The LUGANO trial’s failure to achieve its primary endpoint sharply weakened the clinical and regulatory case for DURAVYU in wet AMD. Analysts have questioned whether the secondary results can compensate for the failed head-to-head outcome. EYPT Stock Plunges After Duravyu Misses Phase III Eye Disease Goal
• Negative Sentiment: Royal Bank of Canada downgraded EyePoint to hold and Chardan Capital cut its rating to neutral; both cited $5 price targets. Cantor Fitzgerald also moved to neutral, while Jefferies lowered its expectations. Chardan, JPMorgan and HC Wainwright otherwise maintained neutral-type views.
• Negative Sentiment: The stock reached a new 12-month low as investors reassessed EyePoint’s valuation, execution risk and dependence on future clinical data. EyePoint Hits New 12-Month Low After Analyst Downgrade

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.